RxDoctor Payments Data

Gail Lowery

Family · Southern Pines, NCNPI 1447782776

Payments from drug & device makers

$7,585in general payments, 2019–2025

Across 431 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$2K
  • Novo Nordisk$801
  • Sanofi-aventis U.S. LLC$478
  • Boehringer Ingelheim$456
  • Abbott$428
  • Radius Health, Inc.$346
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$7,585100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,585 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$86,847
Medicare patients
237
Services billed
2,737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin329$342,614
OzempicSemaglutide251$300,815
MounjaroTirzepatide226$299,132
TrulicityDulaglutide82$110,552
FarxigaDapagliflozin Propanediol114$102,571
Tresiba Flextouch U-100Insulin Degludec147$99,894
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/750$89,103
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog50$84,999
Tresiba Flextouch U-200Insulin Degludec47$69,369
JanuviaSitagliptin Phosphate67$69,303
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog75$48,900
Fiasp FlextouchInsulin Aspart (Niacinamide)39$43,432
Soliqua 100-33Insulin Glargine/Lixisenatide44$42,268
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt19$36,987
Lantus SolostarInsulin Glargine,hum.Rec.Anlog140$32,657

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Insulin Lispro$1,504$447,484372 claims
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Glyxambi$456$402,792396 claims
Novo NordiskOzempic, Fiasp, Novolog$801$331,506304 claims
AstraZenecaFarxiga$192$102,571114 claims
MerckJanuvia, Janumet Xr$93$99,41186 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$478$42,26844 claims
BayerKerendia$324$17,74012 claims
AbbVieSynthroid$103$5,53768 claims
IBSA Pharma Inc.Tirosint$230$2,91715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Southern Pines

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →